Nuveen Asset Management LLC Has $678,000 Stock Holdings in Sientra Inc (NASDAQ:SIEN)
Nuveen Asset Management LLC trimmed its position in shares of Sientra Inc (NASDAQ:SIEN) by 58.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 174,970 shares of the medical instruments supplier’s stock after selling 250,693 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.35% of Sientra worth $678,000 as of its most recent SEC filing.
Several other hedge funds have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Sientra by 22.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 112,335 shares of the medical instruments supplier’s stock valued at $435,000 after purchasing an additional 20,527 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Sientra during the second quarter valued at about $128,000. Bank of America Corp DE boosted its stake in shares of Sientra by 9.1% during the second quarter. Bank of America Corp DE now owns 42,050 shares of the medical instruments supplier’s stock valued at $162,000 after purchasing an additional 3,511 shares in the last quarter. Baird Financial Group Inc. acquired a new stake in shares of Sientra during the second quarter valued at about $1,411,000. Finally, Bank of Montreal Can acquired a new stake in shares of Sientra during the second quarter valued at about $39,000. 76.86% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts have recently commented on SIEN shares. SVB Leerink lifted their price target on Sientra from $5.30 to $6.00 and gave the company an “outperform” rating in a research note on Tuesday, August 11th. Canaccord Genuity reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Sientra in a research note on Friday, August 14th. Maxim Group reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Sientra in a research note on Wednesday, August 12th. Finally, Zacks Investment Research lowered Sientra from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Two investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $6.42.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Monday, August 10th. The medical instruments supplier reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.23). The firm had revenue of $12.45 million for the quarter, compared to the consensus estimate of $8.87 million. Sientra had a negative net margin of 140.76% and a negative return on equity of 130.33%. On average, equities research analysts anticipate that Sientra Inc will post -1.6 earnings per share for the current year.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names.
Read More: Bear Market – How and Why They Occur
Want to see what other hedge funds are holding SIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sientra Inc (NASDAQ:SIEN).
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.